{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T10:21:16Z","timestamp":1698142876906},"reference-count":6,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/jpids\/pix084","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T19:11:17Z","timestamp":1504033877000},"source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics of Ceftaroline in a Preterm Infant With Methicillin-Resistant Staphylococcus Aureus Pneumonia"],"prefix":"10.1093","author":[{"given":"Sara N","family":"Salerno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Laughon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"key":"key\n\t\t\t\t20171016034646_CIT0001","author":"Forest Pharmaceuticals, Inc","year":"2016"},{"key":"key\n\t\t\t\t20171016034646_CIT0002","author":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research"},{"key":"key\n\t\t\t\t20171016034646_CIT0003","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/jcph.809","article-title":"Population PK modeling and target attainment simulations to support dosing of ceftaroline fosamil in pediatric patients with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia","volume":"57","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20171016034646_CIT0004","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.50.4.1376-1383.2006","article-title":"Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target","volume":"50","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171016034646_CIT0005","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40262-015-0291-1","article-title":"Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design","volume":"54","author":"TINN (Treat Infections in NeoNates) and GRiP (Global Research in Paediatrics) Consortiums","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20171016034646_CIT0006","author":"ClinicalTrials.gov"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/doi\/10.1093\/jpids\/pix084\/21300266\/pix084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T07:46:55Z","timestamp":1508140015000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jpids\/article\/doi\/10.1093\/jpids\/pix084\/4554433\/Pharmacokinetics-of-Ceftaroline-in-a-Preterm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":6,"URL":"https:\/\/doi.org\/10.1093\/jpids\/pix084","relation":{},"ISSN":["2048-7193","2048-7207"],"issn-type":[{"value":"2048-7193","type":"print"},{"value":"2048-7207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,16]]}}}